Curesponse is a pioneering leader in precision oncology. Founded on extensive research originating from the esteemed Weizmann Institute of Science on the Tumour-Micro-Environment, and supported by impactful publications, Curesponse is transforming the landscape of cancer care and oncology drug development.
The company has developed a Personal Derived Explants (PDE) platform, with the ability to accurately predict human responses to a diverse range of cancer therapies and oncology drug candidates with an unprecedented accuracy rate. This platform enables personalised matching with the most suitable drug from the outset, maximising the likelihood of a favourable response, reducing unnecessary treatments, and generating cost savings for healthcare systems.
The company operates accredited labs in Israel and in the UK at the London Cancer Hub. and has landmarked a CE mark for Europe and granted patents for EU and US, in its expansion roadmap.
